Methotrexate subcutaneous auto-injection - Antares Pharma

Drug Profile

Methotrexate subcutaneous auto-injection - Antares Pharma

Alternative Names: Otrexup; VIBEX MTX

Latest Information Update: 01 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antares Pharma
  • Class Abortifacients; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Heart failure therapies; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Apr 2016 The US FDA approves interim dosage strengths of methotrexate for treatment of Rheumatoid arthritis, Juvenile rheumatoid arthritis and Psoriasis in USA
  • 07 Sep 2015 Antares Pharma terminates its licence for Methotrexate auto-injection in USA
  • 27 Apr 2015 LEO Pharma terminates its license for methotrexate in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top